A carregar...
Publicação
Equity research report: Johnson & Johnson: a legacy of innovation and steady growth
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 419.97 KB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
This equity research report, prepared as part of Nova SBE’s Field Lab by Justin Jacob and
Rupert Schuler, evaluates Johnson & Johnson (JNJ). Our valuation estimates a share price of
$183, indicating the stock is undervalued compared to its December 13, 2024 market price of
$146.62. A detailed relative valuation and sensitivity analysis across four scenarios support
this conclusion. The report considers JNJ’s operational resilience, ongoing litigations, and
macroeconomic factors, providing a balanced assessment of internal and external influences
on the company’s intrinsic value.
Descrição
Palavras-chave
Drugs Research & Development Valuation Litigations